2009 – Page 5 – Oral Cancer News

Uninsured have higher mortality from head and neck cancer than insured

Source: professional.cancerconsultants.com Author: staff Researchers from the University of Pittsburgh have reported that patients with “Medicaid/uninsured and Medicare disability were at increased risk of death after the diagnosis of squamous cell carcinoma of the head and neck (SCCHN) when compared with patients with private insurance.” The details of this study were published online on November 20, 2009 in Cancer.[1] Unfortunately, underinsured or uninsured patients are reportedly at risk for impaired access to care, delays in medical treatment, and in some cases, substandard medical care. A recent article in the journal Cancer suggests that patients who are uninsured or those who receive Medicaid benefits may be at greater risk for developing postoperative complications and dying after surgery for colorectal cancer. Researchers from the Division of Cancer Prevention and Control and the Kentucky Cancer Registry have previously documented survival differences in patients with and without private health insurance. These findings were reported in the October 13, 2003 issue of the Archives of Internal Medicine. The current study evaluated outcomes of 1,231 patients with head and neck cancer treated at the University of Pittsburgh. Patients were divided into those with Medicaid and uninsured status plus those with Medicare disability versus patients with private insurance. The hazard ratio for survival was 1.50 for patients defined as Medicaid/uninsured versus private insurance. The hazard ration for survival of Medicare disability patients was 1.69 compared with patients with private insurance. These increased rates of death were presented and then corrected for competing risk factors such as alcohol [...]

Oral Cancer Foundation News Team - A2009-11-28T07:28:18-07:00November, 2009|Oral Cancer News|

Should your son get the HPV vaccine?

Source: www.nbc-2.com Author: staff TAMPA: David Hastings is back to helping his wife Jo at their Cuban restaurant outside Saint Petersburg. He's grateful to be here after a very close call. "One morning I was shaving and I noticed this side of my neck was swollen," Hastings explained. The diagnosis: stage four oral cancer. Until then, David was a healthy non-smoker who exercised regularly. "Picture a male drinking and smoking everyday for years and years. That's who gets my cancer. I kept saying people, that's not me." It turns out David's cancer was caused by the human papillomavirus or HPV, a virus he didn't even know he carried. Nancy: "So David's case is not rare?" Dr. Anna Giuliano: "No! Not at all!" From her office at the Moffit Cancer Center in Tampa, Dr. Anna Giuliano is leading an international study on HPV in men. Right now the virus is best known for causing cervical cancer in women. But that is about to change. "Cervical cancer is going down and HPV related head and neck cancer is going up," she explained. Dr. Giuliano says every year between 6 and 8 thousand head and neck cancers in men are HPV-related. "Now we have very definitive evidence that HPV causes cancer in men; the most important being head and neck cancers, penile cancer and anal cancer," she told NBC2. In October, the FDA approved the use of the HPV vaccine Gardasil in males ages 9-26. But Dr. Giuliano worries misinformation will keep young [...]

Oral Cancer Foundation News Team - A2009-11-28T07:19:04-07:00November, 2009|Oral Cancer News|

After being diagnosed, Zenk Pinter is an oral cancer spokesperson

Source: www.acorn-online.com Author: Susan Wolf Colleen Zenk Pinter of Redding, an actor who stars as Barbara Ryan on As the World Turns, has partnered with the Oral Cancer Foundation, Yale New-Haven Hospital and Roswell Park Cancer Institute to be a spokesperson for oral cancer. Ms. Pinter was diagnosed with oral cancer in March 2007 and is now cancer-free. “I had no risk factors for this ‘old man’s cancer,’ she said, but her doctors said hers was probably due to human papilloma virus (HPV), which is most often associated with cervical cancer. HPV is the most common sexually transmitted disease in the country, and it is estimated that about 70% of American men and women will be infected at some point in their lives. According to Ms. Zenk Pinter, a growing number of women are being diagnosed with oral cancer, from one in 10 to now a 50-50 split. “The difference is HPV,” she said. She is a proponent of the Gardasil® vaccine against HPV for both girls and boys. It doesn’t help if only half of the population (girls) is being vaccinated. Why boys? “Simple. HPV is sexually transmitted.” Physicians and researchers advocate that the vaccine be given to both sexes, Ms. Zenk Pinter said. During her speech at New York University School of Dentistry graduation, where she received the 2009 Harry S. Strusser Memorial Award for Public Service and Outstanding Contributions to Public Health, Ms. Zenk Pinter implored the graduating doctors and surgeons to thoroughly check their patients for [...]

Oral Cancer Foundation News Team - A2009-11-28T07:11:44-07:00November, 2009|OCF In The News, Oral Cancer News|

Dental hygiene students screen for oral cancer

Source: uscnews.usc.edu/health Author: Beth Dunham Members of the USC School of Dentistry’s Dental Hygiene Class of 2010 provided oral health screenings and tobacco cessation advice for USC students, staff members and visitors during the American Cancer Society’s Great American Smokeout on Nov. 19. Marked every November with outreach events across the nation, the American Smokeout is designed to help smokers find effective methods to help them quit smoking and highlight the benefits of giving up tobacco. Better oral health and dramatically decreased risk of deadly oral cancer is one huge benefit, said dental hygiene student Allison Clark. Just outside of Bovard Auditorium, the student manned a table stocked with information on oral cancer - including shocking photographs of the damage caused by the disease - and helpful advice on how to successfully quit smoking. Dental hygiene student Lauren Levine said that smokers who turned in at least one cigarette received a prize pack that included a toothbrush and tube of toothpaste, as well as smoking cessation supplies such as gum and information on quitting resources and techniques. They also received a raffle ticket for a chance to win an electric toothbrush. Dental hygiene students conducted oral health screenings at both the USC Pharmacy and School of Dentistry on the University Park campus. Even nonsmokers took the opportunity to receive a free oral health checkup. Staff member Todd Henneman said he thought having a screening was a good idea even though he doesn’t smoke. “I figured that I might as well [...]

Oral Cancer Foundation News Team - A2009-11-23T14:41:49-07:00November, 2009|Oral Cancer News|

American Cancer Society, ENT and Allergy Associates once again partner to fight smoking, especially among teens

Source: www.earthtimes.org Author: press release The American Cancer Society and ENT and Allergy Associates, LLP (ENTA) are once again teaming up to bring a strong and relevant anti-smoking message to teens and ENTA patients through a strategic partnership that includes outreach to local high schools and patient education. “The most effective way for us to fight cancer is to partner with systems in our communities to reach the largest number of people possible,” said Dee McCabe, Executive Vice President, American Cancer Society. “ENTA has been a great partner, reaches thousands of people a day, and truly is committed to improving health of their patients.” “At ENTA, we see far too many patients-each and every week-afflicted with cancer…so our partnership with the American Cancer Society allows us to educate people about the dangers of smoking, and point them toward smoking cessation and cancer prevention” said Dr. Wayne Eisman, President of ENT and Allergy Associates. “We are delighted to do everything we possibly can to help the ACS fight smoking, particularly among young people.” A key part of the alliance is ENTA’s support of the American Cancer Society’s Great American Smokeout, held on November 19th. Throughout the month of November, ENTA will offer patients materials on how to quit smoking in its 30 offices throughout the Greater New York and New Jersey area. Also, several ENTA doctors will speak at local high schools to teens about the dangers of smoking, how to deal with peer pressure, and how the tobacco industry targets [...]

Oral Cancer Foundation News Team - A2009-11-18T16:31:56-07:00November, 2009|Oral Cancer News|

Early PET-CT predicts treatment response of head and neck cancer

Source: www.curetoday.com Author: staff In patients with advanced squamous cell carcinoma of the head and neck, negative findings on post-treatment positron emission tomography/computed tomography (PET-CT) predict a good treatment response, researchers say. In 31 patients with clinical stage III and IV tumors treated with cisplatin and concurrent external beam radiotherapy, PET-CT was performed 6 to 8 weeks after therapy was completed, along with a comprehensive physical examination of the head and neck, as reported by Dr. James P. Malone, from the Southern Illinois School of Medicine, Springfield, and colleagues in the November Archives of Otolaryngology -- Head and Neck Surgery. Seventeen patients had evidence of persistent disease on physical exam, CT, and/or PET-CT, and these individuals had surgery for further evaluation. Fourteen patients had complete clinical responses, including no evidence of FDG uptake on PET-CT; these subjects were observed with routine follow-up. According to the researchers, all but one of these 14 patients remained disease free at the primary tumor site during a median follow-up of 26 months. Thus, the authors point out, the sensitivity of PET-CT was 83%, and its negative predictive value was "excellent" at 92% for detection of persistent disease at the primary tumor site. Because of a high false-positive rate, specificity was low at 54%, with a positive predictive value of 31%. Dr. Malone's group attributes the high false-positive rate to inflammation related to recent treatment. The investigators also note that 5 of 16 patients with abnormal FDG update developed local disease. "For patients with abnormal [...]

Oral Cancer Foundation News Team - A2009-11-18T16:19:03-07:00November, 2009|Oral Cancer News|

Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model

Source: Journal of Biomedical Science Author: Staff The progression and metastasis of solid tumors, including head and neck squamous cell carcinoma (HNSCC), have been related to the behavior of a small subpopulation of cancer stem cells. Here, we have established a highly malignant HNSCC cell line, SASVO3, from primary tumors using three sequential rounds of xenotransplantation. SASVO3 possesses enhanced tumorigenic ability both in vitro and in vivo. Moreover, SASVO3 exhibits properties of cancer stem cells, including that increased the abilities of sphere-forming, the number of side population cells, the potential of transplanted tumor growth and elevated expression of the stem cell marker Bmi1. Injection of SASVO3 into the tail vein of nude mice resulted in lung metastases. These results are consistent with the postulate that the malignant and/or metastasis potential of HNSCC cells may reside in a stem-like subpopulation. Authors: Chi-Yuan ChenShih-Hwa ChiouChih-Yang HuangChia-Ing JanShu-Chun LinMing-Long TsaiJeng-Fan Lo Source: Journal of Biomedical Science 2009, 16:100

Oral Cancer Foundation News Team - A2009-11-19T10:02:44-07:00November, 2009|Oral Cancer News|

Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer

Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study were published early online in the Lancet Oncology on November 7, 2009.[1] Standard treatment for head and neck cancer is largely determined by the stage and by the specific locations within the head or neck area where the cancer has spread. The patient’s overall medical condition is also a deciding factor. Treatment typically consists of radiation therapy, chemotherapy with surgery, or surgery alone. Erbitux is a monoclonal antibody that binds to the epithelial growth factory receptor (EGFR) and inhibits the receptor’s effects on cellular replication. Erbitux is currently FDA-approved for treatment of head and neck cancer. Researchers involved in an international study have previously reported that the addition of Erbitux to radiation therapy improves survival over radiation therapy alone in the treatment of head and neck cancer. The results of this randomized trial with a 54-month follow-up were published in the February 9, 2006, issue of the New England Journal of Medicine. This trial included 424 patients; approximately half were treated with Erbitux plus high-dose radiation therapy, and the other half received high-dose radiation therapy alone. This study now has a follow-up of more than five years. The Following table summarizes some of the findings [...]

Oral Cancer Foundation News Team - A2009-11-17T19:52:44-07:00November, 2009|Oral Cancer News|

Neck response to chemoradiotherapy

Source: Arch Otolaryngol Head Neck Surg. 2009;135(11):1133-1136 Author: Alexander Langerman, MD et al. Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer Objective: The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate. Patients who have a complete radiographic response may not need dissection, and the extent of neck dissection necessary for those patients with residual disease is unclear. Design: Retrospective review of data from a prospectively collected database of patients with locoregionally advanced head and neck cancer treated as part of a phase 2 study of induction chemotherapy followed by concurrent CRT. The results of post-CRT neck computed tomography (CT) imaging and pathologic analysis of the neck dissection specimens were compared to evaluate correlation between radiographic and pathologic response. Results: Forty-nine patients underwent 61 hemineck dissections. Overall, 209 neck levels were dissected. Radiologic complete response in the neck was achieved in 39 patients, all of whom had pathologic specimens negative for tumor cells. Ten patients (20%) had a total of 14 neck levels with residual disease on CT imaging. Five (50%) of these 10 patients were found to have residual tumor cells on pathologic analysis. Tumor cells were contained only to those levels found positive on CT imaging; they were present in 7 (50%) of the 14 positive levels. Conclusions: Neck levels with residual disease on post-CRT CT imaging warrant removal. However, neck levels without evidence of disease on post-CRT CT imaging [...]

Oral Cancer Foundation News Team - A2009-11-17T19:34:20-07:00November, 2009|Oral Cancer News|

Erbitux recognized by ASCO as a 2009 major cancer advance as first SCCHN treatment to improve survival in 30 years

Source: www.vwd.de Author: press release The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck(SCCHN).1 ASCO Clinical Advances Report1 The ASCO report, ‘Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening’, published this week in the Journal of Clinical Oncology, is an independent assessment of the most significant clinical cancer research studies of the past year. Erbitux was singled out for the pivotal first-line SCCHN study, the first randomized trial in 30 years to identify a regimen that increases survival for patients with recurrent and/or metastatic SCCHN. The report commented that, “The ability to improve overall survival with chemotherapy has proven elusive over the last 30 years in several randomized trials comparing different chemotherapy regimens in this setting. Thus, the results of this trial are particularly noteworthy and are changing clinical practice.” This is the second consecutive year that Erbitux has featured in the ASCO ‘Advances’ list.3 In 2008 it was recognized for extending survival in the first-line treatment of NSCLC and for the role of KRAS tumor status in predicting whether patients with newly diagnosed metastatic colorectal cancer will respond to Erbitux.2 “Merck Serono is honored that Erbitux is recognized by ASCO two years in a [...]

Oral Cancer Foundation News Team - A2009-11-16T22:39:55-07:00November, 2009|Oral Cancer News|